1 hour ago | News
Watson Pharmaceuticals CEO Paul Bisaro said the company has around $6 billion to spend on acquisitions as it looks to buy brand-name drug assets, signaling a move away from the company's focus on generic medicines, Bloomberg reported Thursday.
|
19 hours ago | News
THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone ...
|
22 hours ago | News
Watson Pharmaceuticals Inc. said Wednesday it settled a patent lawsuit brought by a unit of Johnson & Johnson over a generic version of the birth control drug Ortho Tri-Cyclen Lo.
|
Feb 8 | News
SAN DIEGO (AP) — Diagnostics company Illumina Inc. again rejected a $5.7 billion offer from Roche AG on Tuesday, saying the Swiss drugmaker's bid was "grossly inadequate."
|
Feb 8 | News
Amgen will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today's meeting of the U.S. FDA Oncologic Drugs Advisory Committee (ODAC).
|
Feb 8 | News
Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix(R) (clopidogrel bisulfate) patent infringement case against Apotex.
|
Feb 7 | News
WASHINGTON (AP) — The Obama administration wants to spend just over half a billion dollars on Alzheimer's research next year, hoping to battle back against what could become the defining disease of the aging baby-boom generation.
|
Feb 7 | News
WASHINGTON (AP) — Scientists for the FDA say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.
|
Feb 7 | News
NEW YORK (AP) — Shares of Anacor Pharmaceuticals Inc. dropped more than 8 percent Monday after the company said its partner GlaxoSmithKline PLC stopped enrolling patients in studies of an anti-infection drug.
|
Feb 7 | News
SAN DIEGO (AP) — Diabetes drug maker Amylin Pharmaceuticals Inc. reported a larger fourth-quarter loss Monday after it ended a partnership with Eli Lilly & Co., which gave Amylin all the rights to the drug Byetta and newly approved Bydureon.
|